Immunovant's total assets for Q3 2026 were $1.05B, an increase of 80.53% from the previous quarter. IMVT total liabilities were $66.26M for the fiscal quarter, a 4.75% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.